Tachykinins, neurotrophism and neurodegenerative diseases: A critical review on the possible role of tachykinins in the aetiology of CNS diseases

Reviews in the Neurosciences

Volumn 7, Issue 3, 1996, Pages 187-214

  Barker, Roger ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Neuro degenerative diseases; Neurotrophism; Receptors; Tachykinins

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROKININ A; NEUROKININ B; SUBSTANCE P; TACHYKININ; TACHYKININ RECEPTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; HUMAN; NEUROMODULATION; NEUROTROPISM; NOCICEPTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SPINAL CORD DORSAL HORN;

EID: 0029858485     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.1996.7.3.187     Document Type: Review

References (270)

1. Agid Y. Parkinson's disease: Pathophysiology. Lancet 1991; 337: 1321-1324.
2. Agid Y, Taquet H, Cesselin F, Epelbaum J, Javoy-Agid F. Neuropeptides and Parkinson's disease. Prog Brain Res 1986; 66: 107-116.
3. Albin RL. Selective neurodegeneration in Huntington's disease. Ann Neurol 1995; 38: 835-836.
4. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. Trends Neurosci 1995; 18: 11-14.
5. Allen JM, Cross AJ, Yeats JC, Ghatei MA, McGregor GP, Close SP, Pay S, Marriott AS, Tyers MB, Crow TJ, Bloom SR. Neuropeptides and dopamine in the marmoset. Brain 1986; 109: 143-157.
6. Anand P, Bannister R, McGregor GP, Ghatei MA, Mulderry PK, Bloom SR. Marked depletion of dorsal spinal cord substance P and calcitonin gene-related peptide with intact skin flare responses in multiple system atrophy. J Neurol Neurosurg Psychiat 1988; 51: 192-196.
7. Ang LC, Shul DD. Peptidergic neurons of subcortical white matter in aging and Alzheimer's brain. Brain Res 1995; 674: 329-335.
8. Anon. Dementia and motorneurone disease. (Editorial) Lancet 1990; i: 1250-1252.
9. Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism and Alzheimer's disease. Ann Neurol; 10: 499-505.
10. Armstrong DM, Terry RD. Substance P immunoreactivity within neuritic plaques. Neurosci Lett 1985; 58: 139-144.
11. Armstrong DM, Benzing WC, Evans J, Terry RD, Shields D, Hansen LA. Substance P and somatostatin coexist within neuritic plaques: implications for the pathogenesis of Alzheimer's disease. Neuroscience 1989; 31: 663-671.
12. Baird A. Fibroblast growth factors: What's in a name? Endocrinology 1993; 132: 487-488.
13. Bannon MJ, Elliott FJ, Alpert JE, Goedert M, Iversen SD, Iversen LL. Role of endogenous substance P in stress-induced activation of mesocortical dopamine neurones. Nature 1983; 306: 791-792.
14. Bannon MJ, Elliott PJ, Bunney EB. Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists. Mol Brain Res 1987; 3: 31-37.
15. Bannon MJ, Haverstick DM, Shibata K, Poosch MS. Preprotachykinin gene expression in the forebrain: Regulation by dopamine. Ann NY Acad Sci 1991; 632: 31-37.
16. Barde, Y-A. What, if anything, is a neurotrophic factor? Trends Neurosci 1988; 11: 343-346.
17. Barker RA. Substance P and Parkinson's disease: A causal relationship? J Theoret Biol 1986; 120: 353-362.
18. Barker R. Substance P and neurodegenerative disorders. A speculative review. Neuropeptides 1991; 20: 73-78.
19. Barker RA, Cahn AP. Parkinson's disease: An autoimmune process. Int J Neurosci 1988; 43: 1-7.
20. Barker RA, Larner AJ. Substance P and multiple sclerosis. Med Hypoth 1992; 37: 40-43.
21. Barker RA, Dunnett SB, Fawcett JW. Neurotrophic factors and neural grafts: a growing field. Sem Neurosci 1993; 5: 431-441.
22. Barnes PJ. Neurogenic inflammation and asthma. J Asthma 1992; 29: 165-180.
23. Beach TG, Tago H, McGeer EG. Light microscopic evidence for a substance P-containing innervation of the human nucleus basalis of Meynert. Brain Res 1987; 408: 251-257.
24. Beal MF. Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38: 357-366.
25. Beal MF, Martin JB. Neuropeptides in neurological disease. Ann Neurol 1986; 20: 547-565.
26. Beal MF, Mazurek MF. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology 1987; 37: 1205-1209.
27. Beal MF, Ellison DW, Mazurek MF, Swartz KJ, Malloy JR, Bird ED, Martin JB. A detailed examination of substance P in pathologically graded cases of Huntington's disease. J Neurol Sci 1988; 84: 51-61.
28. Beck KD, Knüsel B, Hefti F. The nature of the trophic action of brain-derived neurotrophic factor, des (1-3)-insulin-like growth factor-1 and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience 1993; 52: 855-866.
29. Benzing WC, Mufson EJ, Armstrong DM. Immunocytochemical distribution of peptidergic and cholinergic fibers in the human amygdala: their depletion in Alzheimer's disease and morphologic alteration in non-demented elderly with numerous senile plaques. Brain Res 1993; 625: 125-138.
30. Besson MJ, Graybiel AM, Quinn B. Co-expression of neuropeptides in the cat's striatum: an immunohistochemical study of substance P, dynorphin B and enkephalin. Neuroscience 1990; 39: 33-58.
31. Boix F, Mattioli R, Adams F, Huston JP, Schwarting RKW. Effects of substance P on extracellular dopamine in neostriatum and nucleus accumbens. Eur J Pharm 1992; 216: 103-107.
32. Bolam JP, Ingham CA, Izzo PN, Levey AI, Rye DB, Smith AD, Wainer BH. Substance P-containing terminals in synaptic contact with cholinergic neurons in the neostriatum and basal forebrain: a double immunocytochemical study in the rat. Brain Res 1986; 397: 279-289.
33. Bolam JP, Izzo PN. The postsynaptic targets of substance P-immunoreactive terminals in the rat neostriatum with particular reference to identified spiny striatonigral neurons. Exp Brain Res 1988; 70: 361-377.
34. Bost KL, Pascual DW. Substance P: a late-acting B lymphocyte differentiation cofactor. Am J Physiol 1992; 262: C537-545.
35. Bouras C, Vallet PG, Hof PR, Charnay Y, Golaz J, Constantinidis J. Substance P immunoreactivity in Alzheimer disease: A study in cases presenting symmetric or asymmetric cortical atrophy. Alz Dis Assoc Disorders 1990; 4: 24-34.
36. Boysen SJ. Parkinson's disease and electron transport chain. Ann Neurol 1990; 27: 330-331.
37. Brownstein MJ, Mroz EA, Tappaz ML, Leeman SE. On the origin of substance P and glutamic caid decarboxylase (GAD) in the substantia nigra. Brain Res 1977; 135: 315-323.
38. Burcher E, Mussap CJ, Geraghty DP, McClure-Sharp JM, Watkins DM. Concepts in characterization of tachykinin receptors. Ann NY Acad Sci 1991; 632: 123-136.
39. Burgevin M-C, Daniel N, Doble A, Blanchard J-C. The trophic effect of β-amyloid 25-35 peptide is not mediated by NK1 or bombesin receptors. NeuroReport 1992; 3: 1131-1134.
40. Burns RS. Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: A review. Acta Neurol Scand 1991; 84 (Suppl 136): 29-36.
41. Calne DB. Treatment of Parkinson's disease. New Engl J Med 1993; 329: 1021-1027.
42. Calne DB, McGeer E, Eisen A, Spencer P. Alzheimer's disease, Parkinson's disease and motoneurone disease: Abiotopic interaction between aging and environment? Lancet 1986; ii: 1067-1070.
43. Chan-Palay V, Jonsson G, Palay SL. Serotonin and substance P coexist in neurons of the rat's central nervous system. Proc Natl Acad Sci USA 1978; 75: 1582-1586.
44. Chang HC, Gaddum JH. Choline esters in tissue extracts. J Physiol (Lond) 1933; 79: 255-285.
45. Chang MM, Leeman SE, Niall HD. Amino-acid sequence of substance P. Nature New Biol 1971; 232: 86-87.
46. Clevens RA, Beal MF. Substance P-like immunoreactivity in brains with pathological features of Parkinson's and Alzheimer's diseases. Brain Res 1989; 486: 387-390.
47. Clough CG. Parkinson's disease: management. Lancet 1991; 337: 1324-1327.
48. Cramer H, Schaudt D, Rissler K, Strubel D, Warter J-M, Kuntzmann F. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multiinfarct syndrome and communicating hydrocephalus. J Neurol 1985; 232: 346-351.
49. Cramer H, Rissler K, Rosler N, Strubel D, Schaudt D, Kuntzmann F. Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients. Eur Neurol 1989; 29: 1-5.
50. Cramer H, Jost S, Reuner C, Milios E, Geiger J, Mundinger F. Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivity. Neuropeptides 1991; 18: 69-73.
51. Cruz CJ, Beckstead RM. Nigrostriatal dopamine levels are required to maintain basal levels of substance P in the rat substantia nigra. Neuroscience 1989; 30: 331-339.
52. Crystal HA, Davies P. Cortical substance P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. J Neurochem 1982; 38: 1781-1784.
53. Cusick CG. Nerve injury-induced depletion of tachykinin immunoreactivity in the somatosensory cortex of adult squirrel monkeys. Brain Res 1191; 568: 314-318.
54. Davies AM. Switching neurotrophin dependence. Curr Biol 1994; 4: 273-276.
55. Davies AM, Wright EM. Neurotrophin autocrine loops. Curr Biol 1995; 5: 723-726.
56. Davies P, Maloney AJF. Selective loss of cholinergic neurons in Alzheimer's disease. Lancet 1976; ii: 1403.
57. Davies P, Terry RD. Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. Neurobiol Aging 1981; 2: 9-14.
58. de Ceballos ML, Fernanadez A, Jenner P, Marsden CD. Parallel alterations in met-enkephalin and substance-P levels in medial globus pallidus in Parkinson's disease patients. Neurosci Lett 1993; 160: 163-166.
59. De Felipe C, Pinnock RD, Hunt SP. Modulation of chemotropism in the developing spinal cord by substance P. Science 1995; 267: 899-902.
60. Devor M, Wall PD. Plasticity in the spinal cord sensory map following peripheral nerve injury in rats. J Neurosci 1981; 7: 679-684.
61. Dietl MM, Sanchez M, Probst A, Palacios JM. Substance P receptors in the human spinal cord: decrease in amyotrophic lateral sclerosis. Brain Res 1989; 483: 39-49.
62. Dodd J, Kelly JS. The action of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. Brain Res 1981; 205: 337-350.
63. Dreifuss JJ, Raggenbass M. Tachykinins and bombesin excite non-pyramidal neurones in rat hippocampus. J Physiol 1986; 379: 417-428.
64. Dubois B, Hauw JJ, Ruberg M, Serdaru M, Javoy-Agid F, Agid Y. Démence et maladie de Parkinson: Correlations biochimiques et anatomocliniques. Rev Neurol 1985; 141: 184-193.
65. Dunnett SB, Everitt BJ, Robbins TW. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excititoxic lesions. Trends Neurosci 1991; 14: 494-501.
66. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Cochrane RHB, Beeson JAO. Dementia in Parkinson's disease; prevalence and relationship with symptoms and signs of parkinsonism. Psychol Med 1991; 21: 69-76.
67. Eisen A, Calne D. Amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease: phylogenetic disorders of the human neocortex sharing many characteristics. Can J Neurol Sci 1992; 19: 117-120.
68. Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson's disease. New York: Marcel Dekker, 1995.
69. Elliott PJ, Iversen SD. Behavioural effects of tachykinins and related peptides. Brain Res 1986; 381: 68-76.
70. Elliott PJ, Mason GS, Graham EA, Turpin MP, Hagan RM. Modulation of the rat mesolimbic dopamine pathway by neurokinins. Behav Brain Res 1992; 51: 77-82.
71. Emson PC, Arregui A, Clement-Jones V, Sandberg BEB, Rossor M. Regional distribution of methionineenkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain Res 1980; 199: 147-160.
72. Fernandez A, de Cebellos ML, Jenner P, Marsden CD. Striatal neuropeptide levels in Parkinson's disease patients. Neurosci Lett 1992; 145: 171-174.
73. Fernandez A, de Ceballos ML, Jenner P, Marsden CD. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience 1994; 61: 73-79.
74. Ferrier IN, Cross AJ, Johnson JA, Roberts GW, Crow TJ, Corsellis JAN, Lee YC, O'Shaughnessy D, Adrian TE, McGregor GP, Baracese-Hamilton AJ, Bloom SR. Neuropeptides in Alzheimer type dementia J Neurol Sci 1983; 62: 159-170.
75. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci 1991; 14: 220-223.
76. Franck J, Brodin E, Fried K, Rosen A, Yamamoto Y, Fried G. The effect of selective serotoninergic neurotoxin treatment on tachykinin levels in the rat ventral spinal cord. Neuroscience 1991; 45: 339-345.
77. Furtado S, Suchowersky O. Huntington's disease: Recent advances in diagnosis and management. Can J Neurol Sci 1995; 22: 5-12.
78. Gaddum JH. Substance P distribution. In: Schachter M, ed. Polypeptides which Affect Smooth Muscles and Blood Vessels. Oxford: Pergamon, 1960: 163-170.
79. Gai WP, Halliday GM, Blumbergs PC, Geffen LB, Blessing WW. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 1991; 114: 2253-2267.
80. Gajdusek DC. Interference with axonal transport of neurofilament as a common pathogenic mechanism in certain diseases of the nervous system. N Engl J Med 1985; 312: 714-719.
81. Gale JS, Bird ED, Spokes EG, Iversen LL, Jessell T. Human brain substance P: distribution in controls and Huntington's chorea. J Neurochem 1978; 30: 633-634.
82. Geraghty W, Livett BG, Rogerson FM, Burcher E. A novel substance P binding site in bovine adrenal medulla. Neurosci Lett 1990; 112: 276-281.
83. Gerard NP, Bao L, Xiao-Ping H, Gerard C. Molecular aspects of the tachykinin receptors. Reg Peptides 1993; 43: 21-35.
84. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-1432.
85. Gibb WRG. The pathology of parkinsonian disorders. In: Quinn N, Jenner P, eds. Disorders of Movement. London: Academic Press, 1989: 33-57.
86. Gillberg P-G, Aquilonius S-M, Eckernäs S-A, Lundqvist G, Winblad B. Choline acetyltransferase and substance P-like immunoreactivity in the human spinal cord: changes in amyotrophic lateral sclerosis. Brain Res 1982; 250: 394-397.
87. Glass DJ, Yancopoulos GD. The neurotrophins and their receptors. Trends Cell Biol 1993; 3: 262-268.
88. Globus M, Smith MJ, Vethamany-Globus S. Evidence supporting a mitogenic role for substance P in amphibian limb regeneration. Ann NY Acad Sci 1991; 632: 396-399.
89. Goedert M, Hunt SP. The cellular localization of preprotachykinin A messenger RNA in the bovine nervous system. Neuroscience 1987; 22: 983-992.
90. Goto S, Hirano A, Matsumoto S. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex of Guam in comparison with those in Parkinson's and Alzheimer's diseases. Ann Neurol 1990; 27: 520-527.
91. Grafe MR, Forno LS, Eng LF, Immunocytochemical studies of substance P and met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases. J Neuropathol Exp Neurol 1985; 44: 47-59.
92. Haber SN, Watson SJ. The comparative distribution of enkephalin, dynorphin, and substance P in the human globus pallidus and basal forebrain. Neurosci 1985; 14: 1011-1024.
93. Halliday GM, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990a; 510: 104-107.
94. Halliday GM, Gai WP, Blessing WW, Geffen LB. Substance P containing neurons in the pontomesencephalic tegmentum of the human brain. Neuroscience 1990b; 39: 81-96.
95. Hanley MR. Substance P antagonists. Trends Neurosci 1982; 5: 138-140.
96. Hardy J, Adolfsson R, Alafuzoff I, Bucht G, Marcusson J, Nyberg P, Perdahl E, Wester P, Winblad B. Transmitter defects in Alzheimer's disease. Neurochem Int 1985; 7: 545-563.
97. Hasenöhrl RU, Gerhardt P, Huston JP. Positively reinforcing effects of the neurokinin substance P in the basal forebrain: mediation by its C-terminal sequence. Exp Neurol 1992; 115: 282-291.
98. Heike CJ, Charlton CG, Wiley RG. Studies on the cellular localization of spinal cord substance P receptors. Neuroscience 1986; 19: 523-533.
99. Heike CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J 1990; 4: 1606-1615.
100. Hendry SHC, Jones EG, Burstein N. Activity-dependent regulation of tachykinin-like immunoreactivity in neurons of monkey visual cortex. J Neurosci 1988; 8: 1225-1238.
101. Herrera-Marschitz M, Christensson-Nylander I, Sharp T, Staines W, Reid M, Hökfelt T, Terenius L, Ungerstedt U. Striatonigral dynorphin and substance P pathways in the rat. II. Functional analysis. Exp Brain Res 1986; 64: 193-206.
102. Hökfelt T. Neuropeptides in perspective: The last ten years. Neuron 1991; 7: 867-879.
103. Hökfelt T, Ljungdahl A, Terenius L, Eide R, Nilsson G. Immunohistochemical analysis of peptide pathways possibly related to pain and analgesia: Enkephalin and substance P. Proc Natl Acad Sci USA 1977; 74: 3081-3085.
104. Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 1981; 104: 217-247.
105. Hughes AJ, Lees AJ, Stern GM. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990; 336: 32-34.
106. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiat 1992; 55: 181-184.
107. Huston JP, Hasenöhrl RU. The role of neuropeptides in learning: focus on the neurokinin substance P. Behav Brain Res 1995; 66: 117-127.
108. Iadorola MJ, Ofri D, Kleinman JE. Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients. Life Sci 1991; 48: 1919-1930.
109. Inagaki S, Sakanada S, Shiosaka E, Senba K, Takatsuki H, Takagi Y, Kawai H, Minagawa H, Tohyama M. Ontogeny of substance P-containing neuron system in rat: immunohistochemical analysis. I. forebrain and upper brain stem. Neuroscience 1982; 7: 251-277.
110. Iwasaki Y, Kinoshita M, Ikeda K, Takamiya K, Shiojima T. Trophic effect of various neuropeptides on the cultured ventral spinal cord of rat embryo. Neurosci Lett 1989; 101: 316-320.
111. James TA, Starr MS. Effects of substance P injected into the substantia nigra. Br J Pharmac 1979; 65: 423-429.
112. Jenner P, Taquet H, Mauborgne A, Benoliel JT, Cesselin F, Rose S, Javoy-Agid F, Agid Y, Marsden CD. Lack of change in basal ganglia neuropepetide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset. J Neurochem 1986; 47: 1548-1551.
113. Jennings C. How trinucleotide repeats may function. Nature 1995; 378: 127.
114. Johansson O, Hökfelt T, Pernow B, Jeffcoate SL, White N, Steinbusch HWM, Verhofstad AAJ, Emson PC, Spindel E. Immunohistochemical support for three putative transmitters in one neuron: coexistence of 5-hydroxytryptamine, substance P- and thyrotrophin releasing hormone-like immunoreactivity in medullary neurons projecting to the spinal cord. Neuroscience 1981; 10: 1857-1881.
115. Jonakait GM, Ni L, Walker PD, Hart RP. Development of substance P (SP)-containing cells in the central nervous system: Consequences of neurotransmitter co-localization. Prog Neurobiol 1991; 36: 1-21.
116. Jonsson G, Hallman H. Substance P counteracts neurotoxin damage on norepinephrine neurons in rat brain during ontogeny. Science 1982; 215: 75-77.
117. Jonsson G, Hallman H. Substance P modifies the 6-hydroxydopamine induced alteration of postnatal development of central noradrenaline neurons. Neuroscience 1982; 7: 2909-2918.
118. Kage R, McGregor GP, Thim L, Conlon JM. Neuropeptide-γ: a peptide isolated from rabbit intestine that is derived from γ-preprotachykinin. J Neurochem 1988; 50: 1412-1417.
119. Kelley AE, Iversen SD. Behavioural response to bilateral injections of substance P into the substantia nigra of the rat. Brain Res 1978; 158: 474-478.
120. Kostyk SK, Kowall NW, Hauser SL. Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Res 1989; 504: 284-288.
121. Kotani H, Hoshimaru M, Nawa H, Nakanishi S. Structure and gene organization of bovine neuromedin K precursor. Proc Natl Acad Sci USA 1986; 83: 7074-7078.
122. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA. An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proc Natl Acad Sci USA 1991; 88: 7247-7251.
123. Kowall NW, Quigley BJ, Krause JE, Lu F, Kosofsky BE, Ferrante RJ. Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regul Pept 1993; 46: 174-185.
124. Krause JE, Chirgwin JM, Carter MS, Xu ZS, Hershey AD. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc Natl Acad Sci USA 1987; 84: 881-885.
125. Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl 1994; 42: 229-246.
126. Laneuville O, Dorais J, Couture R. Characterization of the effects produced by neurokinins and three agonists selective for neurokinin receptor subtypes in a spinal nociceptive reflex of the rat. Life Sci 1988; 42: 1295-1305.
127. Lauder JM, Bloom FE. Ontogeny of monoamine neurons in the locus coeruleus, raphe nuclei and substantia nigra of the rat. J Comp Neurol 1974; 155: 469-482.
128. Lees AJ. The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford: Butterwoth-Heinemann Ltd, 1987: 110-116.
129. Lees AJ. When did Ray Kennedy's Parkinson's disease begin? Mov Disorders 1992; 7: 110-116.
130. Leigh PN, Ray-Chaudhuri K. Motor neuron disease. J Neurol Neurosurg Psychiat 1994; 57: 886-896.
131. Lembeck F. Concluding remarks. Ann NY Acad Sci 1991; 632: 490-493.
132. Lenders M-B, Peers M-C, Tramu G, Delacourte A, Defossez A, Petit H, Mazzuca M. Dystrophie peptidergic neuntes in senile plaques of Alzheimer's disease hippocampus precede formation of paired helical filaments. Brain Res 1989; 481: 344-349.
133. Lentz SI, Poosch MS, Hirayama K, Kapatos G, Bannon MJ. Substance P gene expression in sympathetic neurons is regulated by neuron/support cell interaction. Dev Brain Res 1993; 73: 35-40.
134. Levine JD, Fields HL, Basbaum AI. Peptides and the primary afferent nociceptor. J Neurosci 1993; 13: 2273-2286.
135. Lindefors N, Brodin E, Tossman U, Segovia J, Ungerstedt U. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation. Exp Brain Res 1989; 74: 527-534.
136. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS. Neurotrophic factors: from molecules to man. Trends Neurosci 1994; 17: 182-190.
137. Lipton SA. Growth factors for neuronal survival and process regeneration. Implications in the mammalian central nervous system. Arch Neurol 1989; 46: 2141-1248.
138. Liu H, Brown JL, Jasmin L, Maggio JE, Vigna SR, Mantyh PW, Basbaum AI. Synaptic relationship between substance P and substance P receptor: Light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. Proc Natl Acad Sci USA 1994; 91: 1009-1013.
139. 11C-labelled NK1 receptor ligand for PET studies. Nucl Med Biol 1995; 22: 31-36.
140. Ljungdahl A, Hökfelt T, Nilsson G. Distribution of substance P-like immunoreactivity in the central nervous system of the rat. I. Cell bodies and nerve terminals. Neuroscience 1978; 3: 861-943.
141. Lo DC. Neurotrophic factors and synaptic plasticity. Neuron 1995; 15: 979-981.
142. Luo CB, Yew DT, Zheng DR, Liu YQ. Acetylcholinesterase-containing neurons, substance P and enkephalin fibers in the ventral horns of developing human embryos and fetuses. Neuroscience 1992; 48: 979-984.
143. McGillis JP, Organist ML, Payan DG. Substance P and immunoregulation. Fed Proc 1987; 46: 196-199.
144. MacDonald MR, Takeda J, Rice CM, Krause JE. Multiple tachykinins are produced and secreted upon posttranslational processing of the three substance P precursor proteins, α-, β-, γ-preprotachykinin. J Biol Chem 1989; 264: 15578-15592.
145. Maggio JE. Tachykinins. Ann Rev Neurosci 1988; 11: 13-28.
146. Maggio JE, Sandberg BEB, Bradley CV, Iversen LL, Santikan S, Williams BH, Hunter JC, Hanley MR. Substance K: a novel tachykinin in mammalian spinal cord. In: Skrabanek P, Powell D, eds. Dublin: Boole, 1983: 20-21.
147. Maggi CA, Patacchini R, Rovero P, Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 1993; 13 : 23-93.
148. Mal JK, Stephens PH, Hopf A, Cuello AC. Substance P in the human brain. Neuroscience 1986; 17: 709-739.
149. Malek-Ahmadi P. Substance P and neuropsychiatric disorders: An overview. Neurosci Biobehav Rev 1992; 16: 365-369.
150. Mantyh PW. Substance P and the inflammatory and immune response. Ann NY Acad Sci 1991; 632: 263-27.
151. Mantyh PW, Hunt SP. The autoradiographic localization of substance P receptors in the rat and bovine spinal cord and the rat and cat spinal trigeminal nucleus pars caudalis and the effects of neonatal capsaicin. Brain Res 1985; 332: 315-324.
152. Mantyh PW, Johnson DJ, Boehmer CG, Catton MD, Vinters HV, Maggio JE, Too H-P, Vigna SR. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci USA 1989; 86: 5193-5197.
153. Martin JE, Swash M. The pathology of motor neuron disease. In: Leigh PN, Swash M, eds. Motor Neuron Disease: Biology and Management. London: Springer-Verlag, 1995: 93-118.
154. 1.11. Neuroscience 1992; 48: 595-605.
155. Meakin SO, Shooter EM. The nerve growth factor family of receptors. Trends Neurosci 1992; 15: 323-331.
156. Mauborgne A, Javoy-Agid F, Legrand JC, Agid Y, Cesselin F. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res 1983; 268: 167-170.
157. Mitrovic B, Martin FC, Charles AC, Ignarro LJ, Anton PA, Shanahan F, Merrill JE. Neurotransmitters and cytokines in CNS pathology. Prog Brain Res 1994; 103: 319-330.
158. Mitsushio H, Takashima M, Mataga N, Toru M. Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: A possible implication of substance P in affective disorders. J Pharm Exp Therap 1988; 245: 982-989.
159. Mitsusmoto H, Hanson MR, Chad DA. Amyotrophic lateral sclerosis. Recent advances in pathogenesis and therapeutic trials. Arch Neurol 1989; 45: 189-202.
160. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. Arch Neurol 1989; 46: 651-657.
161. Nakai K, Kasamatsu T. Accelerated regeneration of central catecholamine fibers in cat occipital cortex: effects of substance P. Brain Res 1984; 323: 374-379.
162. Nakajima Y, Nakajima S, Obata K, Carlson CG, Yamaguchi K. Dissociated cell culture of cholinergic neurons from nucleus basalis of Meynert and other basal forebrain nuclei. Proc Natl Acad Sci USA 1985; 82: 6325-6329.
163. Nakanishi S. Substance P precursor and kininogen: their structures, gene organizations, and regulation. Physiol Rev 1987; 67: 1117-1142.
164. Nakanishi S. Mammalian tachykinin receptors. Ann Rev Neurosci 1991; 14: 123-136.
165. Napier TC, Mitrovic I, Churchill L, Klitenick MA, Lu A-Y, Kalivas PW. Substance P in the ventral pallidum: projection from the ventral striatum, and electrophysiological and behavioral consequences of pallidal substance P. Neuroscience 1995; 69: 59-70.
166. Narumi S, Fujita T. Stimulatory effects of substance P and nerve growth factor (NGF) on neunte outgrowth in embryonic chick dorsal root ganglia. Neuropharmacology 1978; 17: 73-76.
167. Narumi S, Maki Y. Stimulatory effects of substance P on neurite extension and cyclic AMP levels in cultured neuroblastoma cells. J Neurochem 1978; 30: 1321-1326.
168. Nawa H, Hirose T, Takashima H, Inayama S, Nakanishi S. Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursor. Nature 1983; 306: 32-36.
169. Nawa H, Kotani H, Nakanishi S. Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature 1984; 312: 729-734.
170. Neary D, Snowden JS, Mann DMA, Northen B, Goulding PJ, Macdermott N. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiat 1990; 53: 23-32.
171. Nicoll RA. The action of thyrotrophin-releasing hormone, substance P and related peptides on frog spinal motoneurons. J Pharm Exp Therap 1978; 207: 817-824.
172. Nilsson J, von Euler AM, Dalsgaard C-J. Stimulation of connective tissue cell growth by substance P and substance K. Nature 1985; 315: 61-63.
173. Noguchi K, Kawai Y, Fukuoka T, Senba E, Miki K. Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effects on dorsal column nucleus neurons. J Neurosci 1995; 15: 7633-7643.
174. Nutt JG, Mroz EA, Leeman SE, Williams AC, Engel WK, Chase TN. Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomce dysfunction. Neurology 1980; 30: 1280-1285.
175. Ogawa T, Kanazawa I, Kimura S. Regional distribution of substance P, neurokinin α and neurokinin β in rat spinal cord, nerve roots and dorsal root ganglia, and the effects of dorsal root section or spinal transection. Brain Res 1985; 359: 152-157.
176. O'Neill JR, Jaffe H, Hill JM, Barbour GM, Kwart LD, Bowen WD, Ruff MR, Pert CB. Substance P [5-11] inhibits NMDA-induced neurotoxicity both in vitro and in vivo. Soc Neurosci Abstr 1990; 16: 194.
177. Oram JT, Edwardson JA, Nillard PM. Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia. Gerontology 1981; 27: 216-233.
178. Orosz D, Bennett JP. Baseline and apomorphine-induced extracellular levels of nigral substance P are increased in an animal model of Parkinson's disease. Eur J Pharm 1990; 182: 509-514.
179. Otsuka M, Sakuma M, Kobayashi N, Onishi Y, Yanagisawa M, Suzuki H, Yoshioka K. Tachykinin-evoked release of neurotransmitters from isolated spinal cord of the newborn rat. Ann NY Acad Sci 1991; 632: 212-219.
180. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993; 73: 230-308.
181. Parent A, Cote P-Y, Lavoie B. Chemical anatomy of primate basal ganglia. Prog Neurobiol 1995; 46: 131-197.
182. Patterson PH, Nawa H. Neuronal differentiation factors/cytokines and synaptic plasticity. Cell 1993; 72 Suppl: 123-137.
183. Pearson RCA, Powell TPS. The neuroanatomy of Alzheimer's disease. Rev Neurosci 1989; 2: 101-121.
184. Pernow B. Substance P. Pharmacol Rev 1983; 35: 85-141.
185. Perry RH, Dockray GJ, Dimaline R, Perry EK, Blessed G, Tomlinson BE. Neuropeptides in Alzheimer's disease, depression and schizophrenia. J Neurol Sci 1981; 51: 465-472.
186. Peterson GM, Shurlow CL. Morphological evidence for a substance P projection from the medial septum to hippocampus. Peptides 1992; 13: 509-517.
187. Pezzoli G, Panerai AE, Di Giulio A, Longo A, Passerini D, Carenzi A. Methionine-enkephalin, substance P and homovanillic acid in the CSF of parkinsonian patients. Neurology 1984; 34: 516-519.
188. Piccioli P, Luzio AD, Amann R, Schuligoi R, Surani MA, Donnerer J, Cattaneo A. Neuroantibodies: Ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice. Neuron 1995; 15: 373-384.
189. Piercey MF, Schroeder LA, Folkers K, Horig, Xu J-C, Horig J. Sensory and motor functions of spinal cord substance P. Science 1981; 214: 1361-1363.
190. Pinnock RD, Dray A. Differential sensitivity of presumed dopaminergic and non-dopaminergic neurons in rat substantia nigra to electrophorectically applied substance P. Neurosci Lett 1982; 29: 153-158.
191. Pycock CJ. Turning behaviour in animals. Neuroscience 1980; 5: 461-514.
192. Quigley BJ, Kowall NW. Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex. Neuroscience 1991; 41: 41-60.
193. Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiat 1989; 52 (Special Suppl): 78-79.
194. Quirion R, Shults CW, Moody TW, Pert CB, Chase TN, O'Donohue. Autoradiographic distribution of substance P receptors in rat central nervous system. Nature 1983; 303: 714-716.
195. Quirion R, Dam T-V. Multiple tachykinin receptors in guinea pig brain, high densities of substance K (neurokinin A) binding sites in the substantia nigra. Neuropeptides 1985; 6: 191-204.
196. Quirion R, Dam T-V. Ontogeny of substance P receptor binding sites in rat brain. J Neurosci 1986; 6: 2187-2199.
197. Radke JM, Gumming P, Vincent SR. Effects of MPTP poisoning on central somatostatin and substance P levels in the mouse. Eur J Pharm 1987; 134: 105-108.
198. Rajput AH. Frequency and cause of Parkinson's disease. Can J Neurol Sci 1992; 19: 103-107.
199. Rauschecker JP. Mechanisms of visual plasticity: Hebb synapses, NMDA receptors and beyond. Physiol Rev 1991; 71: 587-615.
200. Reid M, Herrera-Marschitz M, Hökfelt T, Terenius L, Ungerstedt U. Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P. Eur J Pharmacol 1988; 147: 411-420.
201. Reid MS, Herrera-Marschitz M, Hökfelt T, Lindefors N, Persson H, Ungerstedt U. Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. Exp Brain Res 1990; 82: 293-303.
202. Reid MS, Hökfelt T, Herrera-Marschitz M, Hakanson R, Feng DM, Folkers K, Goldstein M, Ungerstedt U. Intranigral substance P stimulation of striatal dopamine release is inhibited by Spantide II: a new tachykinin antagonist without apparent neurotoxicity. Brain Res 1990; 532: 175-181.
203. Reiner A, Anderson KD. The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings. Brain Res Rev 1990; 15: 251-265.
204. Richfield EK, Maguire-Zeiss KA, Cox C, Gilmore J, Voorn P. Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann Neurol 1995; 37: 335-343.
205. Riederer P, Lange KW. Pathogenesis of Parkinson's disease. Curr Opin Neurol Neurosurg 1992; 5: 295-300.
206. Rinne UK, Rinne JO, Rinne JK, Laakso K, Laihinen A, Lönnberg P. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. J Neural Transm Suppl 1983; 18: 279-286.
207. Rioux L, Joyce JN. Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1993; 6: 199-210.
208. Robertson HA. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci 1993; 15: 201-206.
209. Robison SH, Bradley WG. DNA damage and chronic neuronal degenerations. J Neurol Sci 1984; 64: 11-20.
210. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
211. Ross CA. When more is less: Pathogenesis of glutamate repeat neurodegenerative diseases. Neuron 1995; 15: 493-496.
212. Rösler N, Reuner C, Geiger J, Rissler K, Cramer H. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease. Peptides 1990; 11: 181-183.
213. Ryall RW. Modulation of cholinergic transmission by substance P. Ciba Found Symp 1982; 91: 267-280.
214. Sakamoto S, Goto S, Ito H, Hirano A. Striosomal organisation of substance P-like immunoreactivity in parkinsonian patient. Neurology 1992; 42: 1071-1075.
215. Sakanada M, Inagaki S, Shiosaka S, Senba E, Takagi H, Takatsuki Y, Kawai H, Lida H, Hara Y, Tohyama M. Ontogeny of substance P-containing neuron system of the rat. Immunohistochemical analysis. II. Lower brain stem. Neuroscience 1982; 7: 1097-1128.
216. Sakurada T, Yamada T, Tan-No K, Manome Y, Sakurada S, Kisara K, Ohba M. Differential effects of substance P analogs on neurokinin 1 receptor agonists in the mouse spinal cord. J Pharm Exp Therap 1991; 259: 205-210.
217. Sakurada T, Kuwahara H, Takahashi K, Sakurada S, Kisara K, Terenius L. Substance P (1-7) antagonizes substance P-induced aversive behaviour in mice. Neurosci Lett 1988; 95: 281-285.
218. Sakurada T, Alufuzoff I, Winblad B, Nordberg A. Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. Brain Res 1990; 521: 329-332.
219. Sanberg PR, Emerich DF, Aebischer P, Amisetti SM, Ouellette W, Koutouzis TK, Cahill DW, Norman AB. Substance P containing polymer implants protect against striatal excitotoxicity. Brain Res 1993; 628: 327-329.
220. Sapp E, Ge P, Aizawa H, Bird E, Penney J, Young AB, Vonsattel J-P, Difiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 1995; 64: 397-404.
221. Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disorders 1993; 8: 271-277.
222. Schapira AHV. MPTP and other Parkinson-inducing agents. Curr Opin Neurol Neurosurg 1992; 5: 396-400.
223. Schapira AHV, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. Anatomic and disease specificity of NADH CoQ reductase (Complex I) deficiency in Parkinson's disease. J Neurochem 1990; 55: 2142-2145.
224. Schätzel HM. Neurotrophic factors: ready to go? Trends Neurosci 1995; 18: 463-464.
225. Schellenberg GD. Genetic dissection of Alzheimer's disease, a heterogenous disorder. Proc Natl Acad Sci USA 1995; 92: 8552-8559.
226. Schoenen J, Reznik M, Delwaide PJ, Vanderharghen J-J. Etude immunocytochimique de la distribution spinale de substance P, des enképhalines, de cholécystokinine et de sérotonine dans la sclérose latérale amyotrophique. CR Soc Biol (Paris) 1985; 179: 528-534.
227. Schwarte JP. Neurotransmitters as neurotrophic factors: a new set of functions. Int Rev Neurobiol 1992; 34: 1-23.
228. Shults CW, Johnston P, Gage FH. Comparison of substance K-like and substance P-like fibers and cells in rat hippocampus. Brain Res 1987; 426: 290-296.
229. Shults CW, Hashimoto R, Brady RM, Gage FH. Dopaminergic cells align along radial glia in the developing mesencephalon of the rat. Neuroscience 1990; 38: 427-438.
230. Singaram C, Ashraf W, Gaumitz EA, Torbey C, Segupta A, Pfeiffer R, Quigley EMM. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995; 346: 861-864.
231. Sivam SP. Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian brains. Neuropeptides 1991; 18: 201-207.
232. Sneddon P. Cotransmission. In: Powis DA, Bunn SJ, eds. Neurotransmitter Release and its Modulation: Biochemical Mechanisms, Physiological Function and Clinical Relevance. Cambridge: Cambridge University Press, 1995: 22-37.
233. Snider WD, Johnson EM. Neurotrophic molecules. Ann Neurol 1989; 26: 489-506.
234. Solberg Y, Silverman WF, Pollack Y. Prenatal ontogeny of tyrosine hydroxylase gene expression in the rat ventral mesencephalon. Dev Brain Res 1993; 73: 91-97.
235. Specht LA, Pickel VM, Joh TH, Reis DJ. Light-microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. I. Early ontogeny. J Comp Neurol 1981; 199: 233-253.
236. Stanfield PR, Nakajima Y, Yamaguchi K. Substance P raises neuronal membrane excitability by reducing inward rectification. Nature 1985; 315: 498-501.
237. Stinus L, Kelley AE, Iversen SD. Increased spontaneous activity following substance P infusion into AlO dopaminergic area. Nature 1978; 276: 616-618.
238. Stoddard SL, Ahlskog JE, Kelly PJ, Tyce GM, Van Heerden JA, Zinsmeister AR, Carmichael SW. Decreased adrenal medullary catecholamines in adrenal transplanted parkinsonian patients compared to nephrectomy patients. Exp Neurol 1989; 104: 218-222.
239. Stoddard SL, Tyce GM, Ahlskog JE, Zinsmeister AR, Carmichael SW. Decreased catecholamine content in parkinsonian adrenal medullae. Exp Neurol 1989; 104: 22-27.
240. Stoddard SL, Tyce GM, Ahlskog JE, Zinsmeister AR, Nelson DK, Carmichael SW. Decreased levels of [Met] enkephalin, neuropeptide Y, substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla. Exp Neurol 1991; 114: 23-27.
241. Stoessl AJ, Szczutkowski E, Glenn B, Watson I. Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Res 1991; 565: 254-262.
242. Stoessl AJ, Polanski E, Frydryszak H. Effects of ageing on tachykinin function in the basal ganglia. Brain Res 1993; 632: 21-28.
243. Strand FL, Rose KJ, Zuccarelli LA, Kume J, Alves SE, Antonawich FJ, Garrett LY. Neuropeptide hormones as neurotrophic factors. Physiol Rev 1991; 71: 1017-1046.
244. Svendsen CN, Kew J, Staley K, Sofroniew MW. Death of developing septal cholinergic neurons following NGF withdrawal in vitro; protection by protein synthesis inhibition. J Neurosci 1994; 14: 75-87.
245. Tamiya R, Hanada M, Kawai Y, Inagaki S, Takagi H. Substance P afferents have synaptic contacts with dopaminergic neurons in the ventral tegmental area of the rat. Neurosci Lett 1990; 110: 11-15.
246. Tan DP, Tsou K. Intranigral injection of dynorphin in combination with substance P on striatal dopamine metabolism in the rat. Brain Res 1988; 443: 310-314.
247. Tanzi RE. A promising animal model of Alzheimer's disease. New Engl J Med 1995; 332: 1512-1513.
248. Taquet H, Javoy-Agid F, Mauborgne A, Benoliel JJ, Agid Y, Legrand JC, Hamon M, Cesselin F. Brain neuropeptides in progressive supranuclear palsy. Brain Res 1987; 411: 178-182.
249. Taquet H, Nomoto M, Rose S, Jenner P, Javoy-Agid F, Mauborgne A, Boneliel JJ, Marsden CD, Legrand JC, Agid Y. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the marmoset following long term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuropeptides 1988; 12: 105-110.
250. Tenuvuo O, Rinne UK, Viljanen MK. Substance P immunoreactivity in the post-mortem parkinsonian brain. Brain Res 1984; 303: 113-1116.
251. Tenuvuo O, Kolhinen O, Laihinen A, Rinne UK. Brain substance P receptors in Parkinson's disease. Adv Neurol 1990; 53: 145-148.
252. Thoenen H. The changing scene of neurotrophic factors. Trends Neurosci 1991; 14: 165-170.
253. Tomokane N, Kitamoto T, Tateishi J, Sato Y. Immunohistochemical quantification of substance P in spinal dorsal horns of patients with multiple system atrophy. J Neurol Neurosurg Psychiat 1991; 54: 535-541.
254. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behavior. Acta Physiol Scand 1971; 82 Suppl 367: 49-68.
255. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand 1971; 82 Suppl 367: 69-93.
256. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-493.
257. Vincent SR, McGeer EG. A substance P projection to the hippocampus. Brain Res 1981; 215: 349-351.
258. Von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931; 72: 74-86.
259. Voorn P, Kalsbeek A, Jorritsma-Byham B, Groenewegen HJ. The pre- and postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat. Neuroscience 1988; 25: 857-887.
260. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's diseases: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990; 79: 581-583.
261. Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea Neuroscience 1988; 25: 419-438.
262. Wessendorf MW, Elde R. The coexistence of serotonin- and substance P-like immunoreactivity in the spinal cord of the rat as shown by immunofluorescent double labeling. J Neurosci 1987; 7: 2352-2363.
263. West CHK, Michael RP. Substance P injections into the ventral tegmentum affect unit activity in mesolimbic terminal regions. Brain Res Bull 1991; 26: 229-233.
264. Whitehouse PJ. Parkinson's disease and Alzheimer's disease: new neurochemical parallels. Mov Disorders 1989; 4 S1: 57-61.
265. Whitty CJ, Kapatos G, Bannon MJ. Neurotrophic effects of substance P on hippocampal neurons in vitro. Neurosci Lett 1993; 164: 141-144.
266. Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis) Mayo Clin Proc 1991; 66: 54-82.
267. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides. Science 1990; 250: 279-282.
268. Yates CM, Harmar AJ, Rose R, Shevard J, Sanchey de Levy G, Simpson J, Maloney AFJ, Gordon A, Fink G. Thyrotrophin releasing hormone, luteinizing hormone-releasing hormone and substance P immunoreactivity in post-mortem brain from cases of Alzheimer type dementia and Down's syndrome. Brain Res 1983; 258: 445-452.
269. Zech M, Bogerts B. Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. Acta Neuropathol (Berl) 1985; 68: 32-38.
270. Zivkovic B, Oblin A, Batholini G. Progabide reverses the nigral substance P reduction induced by chronic impairment of dopaminergic transmission. Eur J Pharm 1985; 112: 253-255.